Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.

Br J Dermatol · 2020 · PMC6972989 · PMID 30916381

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

The incidence of potential immunogenicity‐related adverse events did not indicate a clear trend in any positive ADA patient category compared with ADA ‐ NEG patients through weeks 52–64.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.